Coagulation, Bradykinin, Polyphosphates, and Angioedema
Open access
Peer reviewed
Scollr summary
What this paper is about
This review summarizes the pathophysiological rationale, pharmacology, and clinical evidence supporting FXI inhibition for secondary ischemic stroke prevention and discusses future precision-medicine strategies for patient selection.
Full abstract
Read the full abstract
Abstract Ischemic stroke remains a leading contributor to global mortality and long-term disability, while bleeding complications, particularly intracranial hemorrhage, continue to constrain the use of conventional antithrombotic therapies for secondary prevention. Factor XI (FXI) has emerged as an attractive therapeutic target because it promotes thrombin amplification and pathological thrombus stabilization while contributing only modestly to physiological hemostasis, forming the basis for “hemostasis-sparing” anticoagulation. Current FXI-targeted approaches include oral small-molecule FXIa inhibitors (asundexian and milvexian), antisense oligonucleotides (fesomersen), and monoclonal antibodies (abelacimab and osocimab). Among these, oral FXIa inhibitors appear particularly suited for long-term cerebrovascular prevention because they provide rapid, reversible target inhibition. Phase II trials, including PACIFIC-Stroke and AXIOMATIC-SSP, showed neutral primary efficacy end points but consistently favorable safety outcomes. More recently, the phase III OCEANIC-STROKE trial demonstrated that asundexian 50 mg once daily added to antiplatelet therapy reduced recurrent ischemic stroke by 26% (HR 0.74; 95% CI 0.65–0.84) without a significant increase in major bleeding among patients with noncardioembolic stroke. In contrast, OCEANIC-AF showed inferior efficacy compared with apixaban in atrial fibrillation, suggesting that the therapeutic value of FXIa inhibition is strongly dependent on clinical context. Taken together, this review summarizes the pathophysiological rationale, pharmacology, and clinical evidence supporting FXI inhibition for secondary ischemic stroke prevention and discusses future precision-medicine strategies for patient selection.
Direct answer
What can I do from this paper page?
Use this page to scan "Factor XI(a) Inhibition in Secondary Stroke Prevention: On the Cusp of a New Anticoagulation Paradigm" quickly: start with the summary and abstract, then check the authors, source, topics, and related papers. From here, open Scollr to follow Coagulation, Bradykinin, Polyphosphates, and Angioedema research, save the paper, or map adjacent work.
Research areas
Follow related topics
Citation
BibTeX
@article{AlHorani2026Factor,
title = {Factor XI(a) Inhibition in Secondary Stroke Prevention: On the Cusp of a New Anticoagulation Paradigm},
author = {Rami A. Al‐Horani},
journal = {ACS Pharmacology & Translational Science},
year = {2026},
doi = {10.1021/acsptsci.6c00298},
url = {https://doi.org/10.1021/acsptsci.6c00298}
}FAQ
Using this paper in a discovery workflow
How do I find related work for this paper?
Use the related papers and topic links on this page as starting points. In Scollr, you can also open the paper and build a literature map around its references, citing papers, and related work.
How can I keep up with new Coagulation, Bradykinin, Polyphosphates, and Angioedema research papers?
Follow Coagulation, Bradykinin, Polyphosphates, and Angioedema research in Scollr. New papers from the topic flow into a personalized feed, and you can save useful studies to revisit later.
Can I cite this paper from this page?
This page includes a static BibTeX block for Factor XI(a) Inhibition in Secondary Stroke Prevention: On the Cusp of a New Anticoagulation Paradigm. Always verify the DOI, source, and publication details against the publisher record before submitting a manuscript.
Follow this research in Scollr
Follow the topics and authors behind this paper, save useful studies, and build a literature map when you are ready to go deeper.
Get the app